Clinical Trial Update: Pembrolizumab in Patients With Leptomeningeal Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update for pembrolizumab in patients with leptomeningeal disease has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Disease

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Patients With Leptomeningeal Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-01-26